Jennifer A. Doudna Quotes

we founded Editas Medicine with $43 million in financing from three venture capital firms.

Editas Medicine has an exclusive multimillion-dollar license with Juno Therapeutics to develop T cell therapies

have no doubt, this technology will — someday, somewhere — be used to change the genome of our own species in ways that are heritable, forever altering the genetic composition of human kind.

PGD has also been used for other controversial purposes, such as the birth if so-called savior siblings, destined from the moment of implantation not only to live their own lives, but also to serve as organ or cell donors for a sibling.

in 2011, Rachel and I founded a company called Caribou Biosciences to commercialize the Cas proteins.

It’s not that I was categorically opposed to the idea of scientists and physicians using gene editing to introduce heritable changes into the human genome.

As we began discussing authorship of a white paper summarizing our conclusions, we debated who our target audience should be and what kind of outcome we were hoping to achieve.